AAM Calls For FTC Scrutiny Of Pharmacy Benefit Manager Practices

PBMs Often Fail To Encourage Generic And Biosimilar Use

Pharmacy benefit managers often fail to encourage the use of generic and biosimilar medications and in fact undermine patient access to these more affordable drugs, the Association for Accessible Medicines has told the US Federal Trade Commission.

Dictionary entry for 'scrutiny'
The FTC is in the process of reviewing its horizontal and vertical merger guidelines. • Source: Shutterstock

The Association for Accessible Medicines and its Biosimilars Council have urged the US Federal Trade Commission to investigate the business practices of pharmacy benefit managers, specifically their competitive impact and “various abusive behaviors that undermine patient access to safe, affordable pharmaceutical care.”

The organization called for the FTC to do this in a comment letter responding to a request for information...

More from Generics

More from Products